OraSure Technologies (NASDAQ:OSUR) Gains FDA Nod for Rapid Antigen Test
OraSure Technologies (NASDAQ:OSUR) recently received FDA authorization for a rapid antigen test and a urine-collection sample kit, expanding its reach in at-home diagnostic testing. This development highlights the company's focus on non-invasive sampling and accessible diagnostics, positioning it well within the growing trend of decentralized healthcare. OraSure's debt-free status also provides financial resilience in a dynamic market environment.
OraSure Technologies(OSUR) Stock Options Chain | Quotes & News
This article provides access to the stock options chain, quotes, and news for OraSure Technologies (OSUR). It likely includes financial data and relevant information for investors interested in the company's stock and options.
OraSure (OSUR) Q2 2026 Earnings Call Transcript
OraSure Technologies (OSUR) reported Q2 2026 earnings, exceeding revenue guidance with $30.6 million and showing sequential growth in Diagnostics and Sample Management Solutions. The company highlighted FDA clearances for the Colli-Pee urine collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 test, underscoring its decentralized diagnostics strategy. While the FDA submission for the IntelliQ CT/NG test was withdrawn for resubmission, management reiterated its commitment to 2026 revenue growth and achieving operating cash flow breakeven by early 2027.
Kaltura, Inc. (OSUR): Neil Gagnon group reports 5.8% ownership stake
The Neil Gagnon group has reported a 5.8% beneficial ownership stake in Kaltura, Inc., totaling 8,869,949 shares of common stock. This ownership is distributed among Neil Gagnon personally, Gagnon Securities LLC, and Gagnon Advisors, LLC, with specified sole and shared voting and dispositive powers. The filing clarifies that the group disclaims beneficial ownership of shares held in client and fund accounts.
Enterprise value to EBIT forward of OraSure Technologies, Inc. – BX:EP3
This article provides financial information for OraSure Technologies, Inc. (BX:EP3), specifically focusing on its enterprise value to EBIT forward. The content is presented within the TradingView platform, offering an overview of the company's financial data.
Dimensional Fund Advisors LP Sells 437,763 Shares of OraSure Technologies, Inc. $OSUR
Dimensional Fund Advisors LP reduced its stake in OraSure Technologies by 13.4%, selling 437,763 shares but still holding 2.82 million shares valued at $8.46 million, representing 3.92% of the company. Despite institutional ownership at 93.5%, and a recent insider purchase, analysts maintain a "Reduce" rating with a $3.00 price target, while the stock opened at $4.05, near its 52-week high.
Wall Street Zen Upgrades OraSure Technologies (NASDAQ:OSUR) to Hold
Wall Street Zen has upgraded OraSure Technologies (NASDAQ:OSUR) from a "sell" to a "hold" rating, while Weiss Ratings also improved its rating from "sell (e+)" to "sell (d-)". Despite this, analysts collectively rate the stock as "Reduce" with an average price target of $3.00. The stock opened at $4.05, near its 52-week high, with significant institutional ownership and recent insider buying.
OraSure Technologies (OSUR) Stock Profit Return Faces Cash Flow Doubts
OraSure Technologies (OSUR) recently swung from a deep quarterly loss to a profit of US$0.09 EPS on US$30.6 million revenue, which was a positive development for the diagnostics and sample management specialist. Despite the improved gross margin and new product launches, the stock price reaction was muted, and skeptics point to declining trailing twelve-month revenue and negative operating cash flow as ongoing concerns. Management aims for operating cash flow breakeven by 2027, but the company faces challenges with lumpy funding and execution risks.
OraSure Technologies (OSUR) Stock Profit Return Faces Cash Flow Doubts
OraSure Technologies (OSUR) recently swung to a quarterly profit with a positive EPS of US$0.09 and increased revenue, driven by new product launches and manufacturing insourcing. Despite these positive indicators like improved GAAP gross margin and operating income, the share price reaction was modest, and skeptics point to a decline in trailing twelve-month revenue and negative operating cash flow as concerns about the repeatability and quality of the turnaround. Management is still targeting operating cash flow breakeven in 2027, but issues like a withdrawn product submission add to execution risks.
ORA SURE TECHNOLOGIES INC 2026: Revenue $30.64M, Net income $6.25M, EPS $0.09— 10-Q Summary
OraSure Technologies Inc. (OSUR) reported its quarterly results for 2026, showing revenue of $30.64M, net income of $6.25M, and diluted EPS of $0.09. This represents a significant improvement compared to the prior year, which saw a net loss of ($19.69M) and an EPS of ($0.26), despite a slight revenue decline. The company highlighted operational efficiencies, regulatory clearances for new products, and a strategic focus on R&D for CT/NG and Colli-Pee® trials.
OraSure Technologies Inc (OSUR) (Q2 2026) Earnings Call Highlights: Revenue Surges 9. ...
OraSure Technologies (OSUR) reported strong Q2 2026 results, with total revenue exceeding guidance at $30.6 million, a 9.7% sequential increase, driven by diagnostic and sample management product growth. The company achieved regulatory milestones, including FDA clearance for Colli-Pee Dx and EUA for OraQuick Ebola 2.0, and maintains a solid financial position with $161 million in cash. However, OSUR withdrew its FDA submission for the InteliQuick CT/NG test, delaying its launch, and reported a non-GAAP operating loss of $14.7 million for the quarter.
OraSure Technologies Q2 Earnings Call Highlights
OraSure Technologies reported Q2 revenue of $30.6 million, surpassing guidance, driven by strong public-health diagnostics and sample-management product growth. The company achieved sequential gross-margin improvement and significant regulatory milestones, including FDA clearance for its Colli-Pee Dx urine collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 Rapid Antigen Test. Despite withdrawing its IntelliQuick CT/NG test submission for resubmission, OraSure remains confident in its cash position, expects to reach break-even cash flow from operations by early 2027, and projects Q3 revenue between $29.5 million and $32.5 million.
OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies, Inc. (OSUR) reported its financial results for the second quarter of 2026. The company announced its performance during this period, which is a key indicator of its operational health and market standing. This update provides investors and stakeholders with crucial insights into OraSure's recent financial activities and future prospects.
OraSure Technologies, Inc. Q2 2026 Earnings Call Summary
OraSure Technologies, Inc. characterizes 2026 as a transition year, focusing on executing a focused growth strategy after restructuring. The company reported sequential revenue growth and gross margin expansion, driven by public health demand and operational efficiencies, despite withdrawing an FDA submission for a molecular test to incorporate feedback. Management remains committed to achieving operating cash flow breakeven by 2027 and is prioritizing balance sheet flexibility for future investments.
OraSure Technologies Q2 Earnings Call Highlights
OraSure Technologies (NASDAQ: OSUR) reported strong Q2 results, exceeding revenue guidance with $30.6 million, driven by increased public-health demand and growth in diagnostic and sample-management products. The company achieved key regulatory milestones, including FDA clearance for its Colli-Pee Dx urine collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 test, despite delaying the U.S. launch of its IntelliQuick CT/NG test. OraSure improved its gross margin to 43.5%, ended the quarter debt-free with $161 million in cash, and expects Q3 revenue between $29.5 million and $32.5 million, targeting operating cash-flow break-even by early 2027.
Earnings call transcript: OraSure tops Q2 2026 revenue forecast, shares jump
OraSure Technologies exceeded its Q2 2026 revenue forecast, reporting $30.6 million against an expected $28.83 million, leading to a 6.92% jump in after-hours trading. The company highlighted improving gross margins, new product clearances like Colli-Pee Dx and OraQuick Ebola 2.0, and a strong balance sheet with $161 million in cash and no debt. Despite a delay in the IntelliQuick CT/NG test's FDA clearance, management remains confident in its 2026 revenue growth outlook and target of operating cash flow break-even by early 2027.
OraSure Q2 2026 Earnings: A $22.6 Million Remeasurement Drove GAAP Profit
OraSure Technologies reported Q2 2026 net revenue of $30.6 million, a 2% decrease year-over-year, but achieved GAAP profitability with diluted EPS of $0.09, up from a loss of $0.26. This GAAP profit was primarily due to a $22.6 million reduction in acquisition-related contingent consideration, rather than operational improvements, as non-GAAP operating loss widened to $14.7 million. The company faces ongoing challenges including substantial underlying operating losses, regulatory risks for its CT/NG program, flat core revenue growth, and declining cash reserves.
Press Release: OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies has announced its financial results for the second quarter of 2026. The company reported its performance, providing key figures and insights into its operations during this period. Further details on revenue, expenses, and profitability are expected to be included in the full financial statement.
OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies, Inc. announced its financial results for the second quarter of 2026, reporting total revenue of $30.6 million, a 9.7% sequential increase and above guidance, with improved gross margin. The company also highlighted recent FDA clearances for its Colli-Pee™•Dx at-home urine collection device and Emergency Use Authorization for its OraQuick™ Ebola 2.0 Rapid Antigen Test. OraSure provided Q3 2026 revenue guidance of $29.5 million to $32.5 million and discussed its strategic focus on decentralizing diagnostics and targeted growth initiatives.
OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies, Inc. announced its Q2 2026 financial results, reporting $30.6 million in revenue, a 9.7% sequential increase, and improved gross margin. The company also highlighted key achievements, including FDA clearance for its Colli-Pee™•Dx at-home urine collection device and Emergency Use Authorization for its OraQuick™ Ebola 2.0 Rapid Antigen Test. Despite a year-over-year revenue decrease of 2%, OraSure is pursuing growth initiatives through innovation and strategic collaborations, with Q3 2026 revenue guidance set between $29.5 million and $32.5 million.
OraSure Technologies, Inc. Revenue Breakdown – NASDAQ:OSUR
OraSure Technologies, Inc. (NASDAQ: OSUR) reported total revenue of $115.02 million USD last year. The Human Immunodeficiency Virus segment was its top performer, generating $49.80 million USD, though this was a decrease from $60.80 million USD in the prior year. The United States was the primary revenue contributor, accounting for $78.25 million USD.
OraSure Technologies (OSUR) investor discloses 5.5% stake in common stock
Private Management Group, Inc., an investment adviser, has disclosed a 5.5% beneficial ownership stake in OraSure Technologies Inc. (OSUR) common stock, totaling 3,797,682 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are managed across various separately managed accounts. The account holders are entitled to receive dividends and sale proceeds from these shares.
OraSure Technologies Inc (OSUR) Financial Health: Profitability & Balance Sheet Analysis
OraSure Technologies Inc (OSUR) currently holds a financial score of 6.97, placing it 116th out of 199 companies in the Healthcare Equipment & Supplies industry. While its financial status is deemed robust, its operational efficiency is low. The company recently reported a quarterly revenue of $27.93 million, marking a 6.70% year-over-year decrease, with net profit declining by 39.51% over the same period.
OraSure Technologies Inc (OSUR) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for OraSure Technologies Inc (OSUR), detailing its current risk score, industry ranking, and beta value. It includes various financial metrics such as volatility, maximum drawdown, Sharpe Ratio, and liquidity indicators. The report also notes the neutral impact of the U.S. Dollar Index on the Healthcare Equipment & Supplies industry.
OraSure Technologies (OSUR) Expected to Post Earnings on Wednesday
OraSure Technologies (NASDAQ:OSUR) is scheduled to release its Q2 2026 earnings after market close on Wednesday, August 5th. Analysts anticipate a loss of $0.27 per share on revenue of $28.85 million. Despite a consensus "Reduce" rating and an average price target of $3.00, the stock has seen recent insider buying and increased institutional holdings.
OraSure Technologies Inc (OSUR) Income Statement
This article provides a detailed income statement for OraSure Technologies Inc (OSUR), offering quarterly and annual financial performance data. It includes key metrics such as total revenue, cost of revenue, operating expenses, and net income, allowing users to analyze the company's operational efficiency and profitability over several fiscal periods. The article also provides a FAQ section to help users understand how to interpret the income statement and identifies essential metrics for stock analysis.
OraSure Technologies Inc (OSUR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the major shareholders and institutional holdings of OraSure Technologies Inc (OSUR), including top individual institutional investors and types of shareholder entities. It provides a breakdown of institutional shareholding over recent quarters, displaying the number of institutions, shares held, proportion, and changes. The report also lists ETFs that hold OSUR stock and their respective proportions.
OSUR|OraSure Technologies Inc|Price:3.800|
This article provides a detailed company profile of OraSure Technologies Inc (OSUR), including its background, business scope, and financial data. It highlights the company's focus on decentralizing diagnostics with rapid diagnostic tests and sample collection devices, and lists key executives, institutional shareholdings, and top revenue generators.
OSUR|OraSure Technologies Inc|Price:3.970|Chg%:-0.060
This article provides a detailed financial overview of OraSure Technologies Inc (OSUR), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, and margins across various quarters and fiscal years. The report indicates OraSure Technologies Inc's latest earnings date as August 5, 2026, with an analyst rating of "BUY".
OraSure Technologies Inc (OSUR) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for OraSure Technologies Inc (OSUR), covering operating, investing, and financing activities. It presents extensive financial data including net income, capital expenditures, and free cash flow, alongside explanations of what each cash flow type signifies. The report also addresses frequently asked questions regarding OSUR's cash flow performance and definitions of cash flow metrics.
OraSure Technologies Inc (OSUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for OraSure Technologies Inc (OSUR), categorizing its income by business segments and geographical regions. It highlights that HIV products account for the largest proportion of net product and services revenues, and the United States is the primary regional revenue contributor. The data is presented with proportions for each category, offering insights into the company's financial structure.
OSUR|OraSure Technologies Inc|Price:3.975|Chg%:+0.005
OraSure Technologies Inc (OSUR) shows healthy fundamentals and significant growth potential, despite recent weak stock market performance. The stock is considered fairly valued within the Healthcare Equipment & Supplies industry, with a high institutional ownership. Analysts have rated it as a Buy, with a target price of $5.00, suggesting an upward trend in the medium term.
OraSure Technologies, Inc. Revenue Breakdown – LSX:881351
OraSure Technologies, Inc. (LSX:881351) generated 97.93 million EUR in revenue last year, with its Human Immunodeficiency Virus segment contributing the most at 42.40 million EUR. The United States was the largest regional contributor, accounting for 66.63 million EUR of the company's revenue.
3 Promising Penny Stocks With Market Caps Over $60M
This article highlights three promising penny stocks—OraSure Technologies (OSUR), Castellum (CTM), and Protalix BioTherapeutics (PLX)—each with market caps over $60 million. The companies are presented as financially strong despite some being unprofitable, with details on their operations, recent achievements, and financial health. The analysis emphasizes their potential for long-term growth for investors interested in smaller or newer companies.
3 Promising Penny Stocks With Market Caps Over $60M
This article identifies three promising penny stocks—OraSure Technologies (OSUR), Castellum (CTM), and Protalix BioTherapeutics (PLX)—each with market caps over $60M. It highlights their financial health, recent achievements, and growth prospects, noting that while some are currently unprofitable, they exhibit strong balance sheets and strategic positioning for potential long-term growth. The piece offers a brief overview of each company's operations, market cap, and key financial indicators.
Yorkville Advisors Global LP Invests $1.91 Million in OraSure Technologies, Inc. $OSUR
Yorkville Advisors Global LP has invested $1.91 million in OraSure Technologies, Inc. (OSUR) by purchasing 635,000 shares, representing 1.2% of Yorkville's portfolio. Despite this new institutional interest, analyst sentiment remains cautious with a "Reduce" consensus rating and a $3.00 target price. Concurrently, an insider, Director Steven Kyle Boyd, increased his holdings by over 28% with a $74,750 share purchase.
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. (NASDAQ: OSUR) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will host a conference call on the same day at 5 p.m. Eastern Time to discuss the results. A webcast of the call will be available on OraSure's investor relations website.
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. (NASDAQ: OSUR) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. The company will host a conference call to discuss these results at 5 p.m. Eastern Time on the same day. A webcast of the call will be available on OraSure’s investor relations website.
Enterprise value to revenue forward of OraSure Technologies, Inc. – NASDAQ:OSUR
The article provides a financial metric, "Enterprise value to revenue forward," for OraSure Technologies, Inc. (NASDAQ: OSUR). It appears to be a stub or a data point from a financial platform like TradingView, indicating no specific value or further details beyond the title of the metric itself. The content highlights the company's ticker and exchange, emphasizing its market presence.
OraSure to announce Q2 2026 financial results on August 5
OraSure Technologies, Inc. is scheduled to release its Q2 2026 financial results on August 5, 2026, after the market closes. This will be followed by a quarterly conference call at 5 p.m. ET, which interested investors can access via a webcast on the company’s investor relations page. The company, known for its rapid diagnostic tests and sample collection solutions, will archive the webcast for approximately one year.
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. is scheduled to announce its second-quarter 2026 financial results on Thursday, August 5, 2026. Following the announcement, the company will host a conference call and live audio webcast to discuss the results and provide an update on its business.
OraSure's Q2 results webcast is set for Aug. 5 after market close
OraSure Technologies (NASDAQ: OSUR) will release its second-quarter 2026 financial results on August 5, 2026, after the market closes, followed by a conference call at 5:00 p.m. ET. Investors can access a live webcast of the call on the company's investor relations website, with an archived version available for about a year. Previous earnings-date announcements for OraSure have generally been followed by negative 24-hour stock reactions.
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. (NASDAQ: OSUR) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will also host a conference call at 5 p.m. ET on the same day to discuss these results. A webcast of the call will be available on OraSure's investor relations website for registration and access.
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will also host a conference call at 5 p.m. Eastern Time on the same day to discuss the results. A webcast of the call will be available on OraSure's investor relations website, with an archive available for approximately one year.
Bethlehem’s OraSure gets FDA emergency authorization for Ebola test
OraSure Technologies, a Bethlehem-based developer of diagnostic testing, has received emergency use authorization from the FDA for its second-generation OraQuick Ebola 2.0 Rapid Antigen Test. This test can detect all four known Ebola viruses and can be used on live patients and cadaveric oral fluid. The authorization is particularly critical given the current Ebola outbreak in Central Africa, which includes the Bundibugyo virus for which there is no approved vaccine or treatment.
OraSure wins FDA emergency nod for Ebola test (OSUR:NASDAQ)
OraSure Technologies (OSUR) has received Emergency Use Authorization from the FDA for its second-generation Ebola test, OraQuick Ebola 2.0. This test is designed to detect the virus in both living patients and deceased individuals suspected of having died from the disease. The authorization will allow for rapid detection of Ebola.
OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
OraSure Technologies, Inc. announced it has received Emergency Use Authorization (EUA) from the FDA for its second-generation OraQuick™ Ebola 2.0 Rapid Antigen Test. This enhanced test, developed in cooperation with BARDA, detects all four known Ebola viruses, including Bundibugyo, and can be used on live symptomatic individuals and deceased patients. The company is increasing production to meet demand during the current serious outbreak in Central Africa.
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OraSure Technologies, Inc. (NASDAQ: OSUR) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will host a quarterly conference call to discuss these results at 5 p.m. ET on the same day. A webcast of the call will be available on OraSure's investor relations website for registration and access.
OraSure receives Emergency Use Authorization for second generation Ebola test
OraSure Technologies has received Emergency Use Authorization from the FDA for its second-generation OraQuick Ebola 2.0 Rapid Antigen Test. This new test can detect all four known Ebola viruses and can be used on living patients' blood or oral fluids from those suspected to have died from Ebola. The company plans to increase production of the test, which is manufactured in Bethlehem, to meet potential demand amidst a challenging Ebola outbreak in Central Africa.
Why Has OraSure Technologies (NASDAQ:OSUR) Entered Nasdaq News?
OraSure Technologies (NASDAQ:OSUR) has garnered attention due to a recent market-cycle update focusing on public health readiness, rapid diagnostics, and broader diagnostic testing trends. The article notes that the company is in focus because it received emergency authorization for a second-generation Ebola test. It emphasizes that the content is for general information and not investment advice.
